Metagenomi Therapeutics, Inc.
MGX
Analytical Summary
Metagenomi Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Operating Margin (%)Operating Margin (%) is in the bottom quartile
- Profit Margin (%)Profit Margin (%) is in the bottom quartile
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
-51.8%
Weak
Weak
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-747%)
|
16.8%
Good
Good
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+111%)
|
— | — |
| EPS Growth YoY (%) |
0.0%
Caution
Caution
Year-over-year change in earnings per share
Optimal:
> 10%
|
88.2%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-12.6%
Weak
Weak
Year-over-year change in net income |
-14.4%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
29.3%
Excellent
Excellent
Year-over-year change in free cash flow |
88.6%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Operating Margin (%) (%) |
-380.9%
Weak
↓
Weak
Declining
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-2639%)
|
-170.0%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1233%)
|
-175.4%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1269%)
|
— |
| Effective Tax Rate (%) (%) |
0.1%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
6.6%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-13.3%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| Profit Margin (%) (%) |
-348.5%
Weak
↓
Weak
Declining
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-3005%)
|
-149.3%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1344%)
|
-152.5%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1371%)
|
— |
| FCF Margin (%) (%) |
-354.9%
Weak
↓
Weak
Declining
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-214.5%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-226.2%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
| FCF / Net Income (x) |
1.02x
Fair
↓
Fair
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.44x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.48x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-60.5%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-35.4%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
65.6%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-43.4%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-27.4%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-21.5%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-55.4%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-469%)
|
-33.2%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-322%)
|
50.3%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+236%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $25.21M | $52.30M | $44.76M | — |
| Depreciation Expense (USD) | $5.32M | $5.41M | $4.21M | — |
| Net Income, GAAP (USD) | $-87.87M | $-78.06M | $-68.25M | — |
| Operating Cash Flow (USD) | $-88.89M | $-109.07M | $-91.41M | — |
Secondary lens
Benchmark Lens
Compare MGX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare MGX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for MGX
No bullish signals detected
Operating Margin (%) is in the bottom quartile
Profit Margin (%) is in the bottom quartile
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How MGX compares to all companies
Peer Comparison
MGX vs similar peers
Compare MGX with peers
Stack MGX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters